ALSO NOTED: Elixir, Siena team up; Generic cholesterol drug prescriptions on the rise; and much more...

> More cholesterol-lowering drugs are being prescribed as generic formulas of the drugs hit the market. Release

> Elixir Pharmaceuticals and Siena Biotech have entered into an agreement to collaborate on the optimization, validation and evaluation of Elixir's SIRT1 inhibitors in Huntington's disease. Release

> Generic drugmaker Actavis Group acquired a division of India-based Sanmar Specialty Chemicals. Activis hopes the acquisition will reduce manufacturing costs. Report

> PE firm Avista Capital Partners said it will acquire BioReliance Corporation, a business unit of Invitrogen Corporation $210 million. Release

And Finally... Denmark's biotech industry is heating up. Report (WSJ sub. req.)

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.